Tenofovir alafenamide/emtricitabine — Competitive Intelligence Brief

Tenofovir alafenamide/emtricitabine (Tenofovir alafenamide/emtricitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide/nucleoside reverse transcriptase inhibitor combination. Area: Infectious Disease.

marketed Nucleotide/nucleoside reverse transcriptase inhibitor combination HIV reverse transcriptase Infectious Disease Small molecule

Target snapshot

Tenofovir alafenamide/emtricitabine (Tenofovir alafenamide/emtricitabine) — ViiV Healthcare. Tenofovir alafenamide and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tenofovir alafenamide/emtricitabine TARGET	Tenofovir alafenamide/emtricitabine	ViiV Healthcare	marketed	Nucleotide/nucleoside reverse transcriptase inhibitor combination	HIV reverse transcriptase
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
TAF/FTC FDC	TAF/FTC FDC	Janssen Scientific Affairs, LLC	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Cabotegravir LA + Rilpivirine LA	Cabotegravir LA + Rilpivirine LA	Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia	marketed	Antiretroviral combination (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase
TAF with a boosted protease inhibitor	TAF with a boosted protease inhibitor	University of Colorado, Denver	marketed	Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor)	HIV reverse transcriptase and HIV protease
Nevirapine, FTC, and Tenofovir	Nevirapine, FTC, and Tenofovir	University of Maryland, Baltimore	marketed	Antiretroviral combination (NNRTI + NRTI + NtRI)	HIV reverse transcriptase, HIV integrase
Bictegravir, emtricitabine, and tenofovir alafenamide	Bictegravir, emtricitabine, and tenofovir alafenamide	CAN Community Health	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide/nucleoside reverse transcriptase inhibitor combination class)

1. ViiV Healthcare · 1 drug in this class